Ads
related to: actemra indications for medication administration- Patient Support Services
Visit The Site To Learn About
Patient Access Services.
- Clinical Information
View Efficacy & Safety Info Across
Multiple Clinical Studies
- Contact A Representative
Contact A Representative To
Get More Info About ACTEMRA®.
- Important Safety Info
Read The Full Safety Profile
Including Boxed Warning.
- Efficacy & Safety
Learn About The Efficacy & Safety
Before Prescribing To Your Patients
- Coverage Map For HCPs
Fill Out Form To Request
A Local Coverage Map
- Patient Support Services
Search results
Results From The WOW.Com Content Network
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
The first approved medication in this class, tocilizumab (Actemra), is an antibody directed against the IL6-receptor. [8] The second, siltuximab (Sylvant), is directed against IL-6 itself. [ 1 ] [ 9 ] Siltuximab is approved for treatment of human immunodeficiency virus-negative and HHV-8 -negative patients with multicentric Castleman's disease .
Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab.
Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease, [4] [5] rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB. [6] [7] [2]
Illustration of a Hand affected by Rheumatoid arthritis. Rheumatoid Arthritis (RA) is an inflammatory disease that's caused by an autoimmune condition. The condition occurs when bodily cells begin to attack and target their own healthy joint tissues resulting in redness, inflammation, and pain.
The U.S. Food and Drug Administration (FDA) approved just the first MASH treatment last year, although some 22 million patients in the U.S. live with the disease (including 9 million with ...
Ads
related to: actemra indications for medication administration